Source: Annual Congress 2010 - Mechanisms of late allograft dysfunction: new insights



Rating:

Share or cite this content

Citations should be made in the following way:
T. Oumeraci, J. Gottlieb, T. Wolf, B. Brors, A. Pich, A. Haverich, R. Eils, B. Schlegelberger, T. Welte, M. Zapatka, N. von Neuhoff (Heidelberg, Germany). Crossing the divide between clinical BOS risk prediction and proteomic BALF biomarkers. Eur Respir J 2010; 36: Suppl. 54, 1682

Member's Comments

No comment yet.

Related content which might interest you: Comparison among BAL biomarkers in ILD discrimination and course prediction Source: Virtual Congress 2020 – Genetics and biomarkers for diagnosis and prognosis of granulomatous lung diseases Year: 2020 Blood biomarker algorithms to guide COPD assessment and risk stratification Source: International Congress 2017 – Towards personalised medicine in COPD: biological and clinical phenotypes Year: 2017 Novel patterns of serum biomarkers profiling using minimal important clinical outcomes (MICO) in the longidutinal study BODE cohort of COPD patients Source: Annual Congress 2010 - COPD: symptoms and staging Year: 2010 Are biomarkers helpful in sepsis for risk assessment or clinical trials? Source: Annual Congress 2011 - Molecular biomarkers at the bedside of critically ill patients Year: 2011 Mortality risk prediction in COPD by a prognostic biomarker panel Source: Eur Respir J 2014; 44: 1557-1570 Year: 2014 Plasma metabolomic signature in COPD patients: Associations to proteomic profile and clinical outcomes Source: Annual Congress 2013 –COPD mechanisms Year: 2013 Harvesting biomarkers for early risk assessment Source: Annual Congress 2008 - New age lung carcinogenesis: clinical impact Year: 2008 Blood biomarkers predicting disease progression in patients with IPF: data from the INMARK trial Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia Year: 2019 Imaging and molecular biomarkers: a novel approach to screen populations at risk of pulmonary fibrosis? Source: Eur Respir J 2016; 48: 1271-1273 Year: 2016 Proteomic analysis of sputum from adults with cystic fibrosis and COPD: identification of potential biomarkers for disease monitoring Source: Eur Respir J 2006; 28: Suppl. 50, 152s Year: 2006 The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis? Source: International Congress 2017 – Rare diseases Year: 2017 Non-targeted integrative multi-omics approaches on sputum reveal potential diagnostic and monitoring biomarkers for respiratory diseases Source: International Congress 2017 – Novel molecular and genetic targets in COPD Year: 2017 Mortality risk prediction in COPD by a prognostic biomarker panel – Results of a derivation and validation cohort with a long term follow-up Source: International Congress 2014 – Markers Year: 2014 Serum KL-6 as a biomarker to assess risk of worse outcome in patients with SARS-CoV2 infection Source: Virtual Congress 2021 – COVID - 19 biomarkers Year: 2021 Serum microRNA signatures identified in a genome-wide profiling predict the mortality of patients with sepsis Source: Annual Congress 2011 - New aspects in prevention and treatment of community-acquired pneumonia and lower respiratory tract infections Year: 2011 Metabolomic profiling of clinical sputum samples reveals novel biomarkers for the early identification of lung cancer patients Source: International Congress 2014 – Improving diagnosis of thoracic tumours Year: 2014 Neutrophil-to-lymphocyte ratio in IPF patients: a novel prognostic biomarker? Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 Differences in plasma and sputum biomarkers between COPD and COPD-asthma overlap Source: Annual Congress 2013 –Is it really asthma? Year: 2013 Prediction of longitudinal inflammatory phenotypes using baseline sputum transcriptomics in UBIOPRED Source: International Congress 2019 – Novel methods, diagnostics and biomarkers in chronic lung diseases Year: 2019 Pulmonary transplantation and bronchiolitis obliterans syndrome: characterisation of diagnostic biomarkers in bronchioloalveolar lavage fluid by SELDI-TOF proteomic analysis Source: Annual Congress 2009 - Bronchiolitis obliterans syndrome after lung transplantation: pathophysiology and treatment options Year: 2009